Journal: Arthritis and Rheumatism
Article Title: A secretagogue-siRNA conjugate confers resistance to cytotoxicity in a cell model of Sj?gren's syndrome
doi: 10.1002/art.30450
Figure Lengend Snippet: Carbachol and siRNA portions of conjugate retained function after conjugation. (A) Scheme presenting the two-step activation and conjugation of choline to 5’-amino-modified RNA. Activation of choline was carried out by reaction with 4-nitrophenyl chloroformate followed by reaction with amino-modified RNA. (B) Caspase-3 gene expression after transfection of siRNA, conjugate, or negative control conjugate. Free siCaspase-3 treatment indicates naked siRNA targeting caspase-3 was added to the cells in the absence of transfecting reagent. Negative control conjugate contains a scrambled siRNA sequence. Asterisks indicate p<0.05 compared to negative control conjugate as determined by one-way ANOVA with Dunnett's multiple comparison test. (C) Conjugate was added to HSG cells as indicated and intracellular calcium release was measured as fluorescence intensity. Bars represent mean with standard error (n=3 independent experiments), and dashed line indicates level of background fluorescence. (D) Calcium imaging of Parc5 cells treated with 100μM carbachol, a free siRNA control, or 8.7μM conjugate. Each colored line represents calcium response in a single cell.
Article Snippet: The FAM-labeled DNA oligo probe specific for the antisense strand of caspase-3 siRNA (Exiqon Woburn, MA) was diluted to 80nM in PBS and heated to 80°C for two minutes before addition to the cells.
Techniques: Conjugation Assay, Activation Assay, Modification, Expressing, Transfection, Negative Control, Sequencing, Fluorescence, Imaging